AQR Capital Management
AGRX

AQR Capital Management’s Agile Therapeutics AGRX Stock Holding History

AQR Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31
Closed -$178K – 2298
2020
Q4 		$178K Buy
31
+2
+7% +$11.8K ﹤0.01% 2103
2020
Q3 		$179K Buy
+29
New +$166K ﹤0.01% 2078

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

AQR Capital Management's AGRX Position: Q1 2021 in Review

AQR Capital Management sold out of Agile Therapeutics (AGRX) in Q1 2021, closing a stake of 31 shares — an estimated $178K sold.

AQR Capital Management first reported a position in AGRX in Q3 2020 and held it in 2 quarters. The position peaked at $179K in Q3 2020. 73 funds tracked by Wall St. Rank hold AGRX as of Q1 2021.

  • AQR Capital Management reported no remaining Agile Therapeutics position as of Q1 2021 after selling out during the quarter.
  • AQR Capital Management sold 31 Agile Therapeutics shares in Q1 2021, an estimated $178K.
  • AQR Capital Management first reported a position in Agile Therapeutics in Q3 2020 and held it in 2 quarters.
  • AQR Capital Management's Agile Therapeutics position peaked at $179K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2021.

Based on AQR Capital Management's 13F filing for Q1 2021, filed 17 May 2021.